PaperInterferon alpha and 5′-deoxy-5-fluorouridine in colon cancer: Effects as single agents and in combination on growth of xenograft tumours
References (34)
- et al.
Interactions of interferon-alpha2a with 5′deoxy-5fluorouridine in colorectal cancer cells in vitro
Eur J Cancer
(1992) - et al.
Prospective randomised trial comparing fluorouracil versus doxifluridine for the treatment of advanced colorectal cancer
Eur J Cancer
(1993) - et al.
Tumor inhibitory effects of a new fluorouracil derivative: 5′-deoxy-5-fluorouridine
Eur J Cancer
(1980) - et al.
Complete replacement of serum in primary cultures of erythropoietin-dependent red cell precursors (CFU-E) by albumin, transferrin, iron, unsaturated fatty acid, lecithin, and cholesterol
Exp Cell Res
(1980) - et al.
Comparison of the pyrimidine nucleoside phosphorylase activity in human tumors and normal tissues
Exp Pathol
(1988) - et al.
Phase II clinical trial of doxifluridine in patients with advanced ovarian cancer
Eur J Cancer
(1991) - et al.
Stimulation of 5-fluorouracil metabolic activation by interferon-α in human colon carcinoma cells
Biochem Biophys Res Commun
(1992) - et al.
Phase I trial of 5fluorouracil and recombinant at,. -interferon in patients with advanced colorectal carcinoma
Cancer Res
(1990) - et al.
Interferon alpha-2α and 5-fluorouracil for advanced colorectal carcinoma
Cancer
(1990) - et al.
Phase II trial of fluorouracil and recombinant interferon alfa-2a in patients with advanced colorectal carcinoma: an Eastern Cooperative Oncology Group study
J Clin Oncol
(1991)
Phase II study of fluorouracil and recombinant interferon alfa-2a in previously untreated advanced colorectal carcinoma
J Clin Oncol
(1990)
Interaction of fluorouracil and interferon in human colon cancer cell lines—cytotoxic and cytokinetic effects
Cancer Res
(1990)
The therapeutic effects of orally administered 5′-deoxy-5-fluorouridine, l-(2-tetrahydrofuryl)-5fluorouracil and 5-fluorouracil on experimental murine tumors
Jpn J Cancer Res
(1985)
Comparative studies on the immunosuppressive effect amoung 5′deoxy-5-fluorouridine, ftorafur, and 5-fluorouracil
Jpn J Cancer Res
(1980)
Decreased immunosuppression associated with antitumor activity of 5′-deoxy5-fluorouridine compared to 5-fluorouracil and 5-fluorouridine
Cancer Res
(1983)
Cytokines induce thymidine phosphorylase in tumor cells and make them more susceptible to 5′-deoxy-5-fluorouridine
Cancer Chemother Pharmacol
(1993)
Characterization of WiDr: a human colon carcinoma cell line
In Vitro Cell Dev Biol
(1979)
Cited by (10)
Overexpression of pyrimidine nucleoside phosphorylase enhances the sensitivity to 5′-deoxy-5-fluorouridine in tumour cells in vitro and in vivo
2002, European Journal of CancerCitation Excerpt :It has been difficult to find suitable medical treatments against advanced colorectal adenocarcinomas, including those with invasion, dissemination and metastasis with multiple lesions. 5-Fluorouracil (5-FU) is representative of the anticancer agents that are most effective [1–7], although only 5–20% of the patients respond in advanced colorectal cancer [8]. The application of 5-FU is limited due to side-effects including gastrointestinal toxicity and myelosuppression.
Purification, cloning, and expression of murine uridine phosphorylase
1995, Journal of Biological ChemistryPatient-derived xenograft model in colorectal cancer basic and translational research
2023, Animal Models and Experimental MedicineCan immunotherapy reinforce chemotherapy efficacy? a new perspective on colorectal cancer treatment
2023, Frontiers in ImmunologyPotential for predicting toxicity and response of fluoropyrimidines in patients
2004, Current Drug Targets
Copyright © 1994 Published by Elsevier Ltd.